Skip to content

Clinical trials

Phase 1 Lung Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lung Neoplasms Phase: Phase 1 Country / region: China Clear all

62 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20112
20121
20143
20152
20163
20173
20183
20191
20201
20215
20225
20239
20249
202510
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting22
Unknown status21
Completed9
Not yet recruiting5
Active, not recruiting1
Withdrawn1
Enrolling by invitation1
Suspended1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Peking Union Medical College Hospital6
Second Affiliated Hospital of Guangzhou Medical University5
Chongqing Precision Biotech Co., Ltd4
Shanghai Yunying Medical Technology3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2
Guangzhou Institute of Respiratory Disease2
Shanghai Chest Hospital2
Sichuan Baili Pharmaceutical Co., Ltd.2
Alliancells-PuRui Biocience Co., Ltd.1
Anhui Provincial Hospital1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lung Neoplasms62
Breast Neoplasms17
Carcinoma, Non-Small-Cell Lung13
Pancreatic Neoplasms12
Ovarian Neoplasms11
Colorectal Neoplasms10
Esophageal Neoplasms10
Melanoma9
Stomach Neoplasms8
Colonic Neoplasms6

Trials

Showing 1 to 25 of 62. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.